Ipsen has announced that the U.S. Food and Drug Administration has granted accelerated approval for Iqirvo® 80 mg tablets. This medication is for treating primary biliary cholangitis and can be prescribed in combination

Can-Fite BioPharma Ltd., a company focused on developing proprietary small molecule drugs for cancer and inflammatory diseases, has announced that the Institutional Review Board (IRB) at Rabin Medical Center

Calico Life Sciences LLC, a biotechnology company co-founded by Alphabet and Arthur D. Levinson, Ph.D., has announced that their investigational drug fosigotifator has been accepted into the FDA's START Pilot Program.

BWXT Medical Ltd. has filed a Drug Master File with the U.S. Food and Drug Administration for its No Carrier Added Actinium-225 Active Pharmaceutical Ingredient. Ac-225, an alpha-emitting isotope, is pivotal in targeted alpha therapy, where it is combined

Qu Biologics Inc., a biopharmaceutical company focused on developing Site Specific Immunomodulators (SSIs) to enhance innate immune function, has partnered with Foundation Medicine, Inc

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, has advanced revumenib, its oral menin inhibitor, into the Phase 1b segment of its ongoing Phase 1/2 trial. This phase tests revumenib as a monotherapy for patients

XTL Biopharmaceuticals Ltd. announced today that it has entered into a definitive share purchase agreement with the current shareholders of THE SOCIAL PROXY Ltd., an AI web data company that develops

Resolution Therapeutics Limited, a clinical-stage biopharmaceutical company focused on macrophage cell therapies for end-stage liver disease, has announced key data presentations in collaboration

VILYA, Inc., a biotech company focused on creating innovative medicines targeting disease biology with precision, has announced a significant expansion of their Series A financing, totaling $71 million. ARCH Venture Partners, the founding and lead investor, is joined by other top-tier life science

Quell Therapeutics Ltd, a leading developer of engineered T-regulatory cell therapies for serious immune-driven medical conditions, has announced the advancement of its autologous engineered CAR-Treg cell therapy